
• Reported GAAP EPS of $2.47 up 36.46% YoY • Reported revenue of $49.31B up 9.61% YoY • Elevance Health projects FY 2026 GAAP diluted EPS to be at least $22.30 and adjusted diluted EPS at least $25.50, with operating cash flow expected to be at least $5.5 billion.
Bullish
Elevance Health achieved strong revenue growth, with Carelon segment revenue increasing 27% in Q4 2025, and returned $4.1 billion in capital to shareholders during 2025.
Bearish
Elevance Health faced increased medical cost trends, leading to a higher benefit expense ratio and an adjusted operating loss in Health Benefits, alongside a 1% decrease in medical membership.